8-K: agilon health Q4/FY25 Results: Breakeven EBITDA Targeted for 2026

agilon health reported significant losses for fiscal year 2025 but projects a return to breakeven Adjusted EBITDA in 2026 driven by strategic transformation initiatives.

Summary

• Total members on the agilon platform decreased to 625,000 as of December 31, 2025, comprising 511,000 Medicare Advantage members and 114,000 ACO model beneficiaries.
• Total revenue for fiscal year 2025 was $5.93 billion, a 2% decrease compared to $6.06 billion in 2024.
• The company reported a gross loss of $160 million for fiscal year 2025, a significant decline from a gross profit of $5 million in 2024.
• Net loss for fiscal year 2025 was $391 million, compared to a net loss of $260 million in 2024.
• Medical margin was negative $57 million for fiscal year 2025, down from earnings of $205 million in 2024.
• Adjusted EBITDA loss for fiscal year 2025 was $296 million, compared to a loss of $154 million in 2024.
• For fiscal year 2026, agilon health projects total revenues between $5.41 billion and $5.58 billion.
• Medical margin for 2026 is guided to be between $300 million and $350 million.
• Adjusted EBITDA for 2026 is expected to be between a loss of $15 million and a profit of $15 million, with a breakeven midpoint.
• Membership is expected to decrease in 2026, with total members live on platform projected between 525,000 and 540,000, due to payor contract and market exits.
• Operating expenses are expected to be reduced by $35 million for 2026, with selling, general and administrative expenses projected at approximately $234 million.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral-to-slightly-positive outlook. While 2025 results were significantly negative, the company has outlined clear transformation initiatives and provided 2026 guidance that projects a substantial financial turnaround, indicating a potential stabilization and recovery.

Positives

• The company is targeting breakeven Adjusted EBITDA for 2026 at the midpoint of its guidance, a significant improvement from a $296 million loss in 2025.
• Anticipated Medical Margin for 2026 is $300 million to $350 million, a substantial turnaround from a negative $57 million in 2025.
• Operating Expenses are projected to be reduced by $35 million for 2026, reflecting cost rationalization and overhead reductions.
• A strong balance sheet is maintained with approximately $285 million in cash and short-term investments as of December 31, 2025.
• The credit facility has been extended to 2028, supported by existing lenders.
• Improved data visibility now covers approximately 85% of membership, enhancing baseline risk adjustment factor (RAF) accuracy.
• Part D exposure has been reduced to less than 15% of membership, mitigating risk.
• Enhanced Quality Incentives are expected to more than double the 2025 contribution.
• 75% of agilon members are in 4+ Star plans for Payment Year 2027 (PY27), with agilon-specific performance delivering 4.2 consolidated stars on average for PY27.

Negatives

• Reported a significant net loss of $391 million for fiscal year 2025, a 50% increase from the $260 million loss in 2024.
• Experienced a gross loss of $160 million for fiscal year 2025, a sharp decline from a gross profit of $5 million in 2024.
• Medical margin was negative $57 million for fiscal year 2025, a substantial decrease from $205 million in 2024.
• Adjusted EBITDA loss for fiscal year 2025 was $296 million, nearly double the $154 million loss reported in 2024.
• Total members live on platform decreased to 625,000 as of December 31, 2025, from 659,000 in 2024, primarily due to previously disclosed market exits.
• Expected total members live on platform for 2026 are projected to further decrease to between 525,000 and 540,000, reflecting additional payor contract and market exits.
• Elevated medical cost trend is expected to remain slightly above 2025, with an estimated gross cost trend of 7.5% and 7.0% net for 2026.

Risks

• A history of net losses and the expectation that expenses will increase in the future.
• Failure to identify and develop successful new geographies, physician partners, and payors, or execute upon growth initiatives.
• Medical expenses incurred on behalf of members may exceed revenues received.
• Ability to maintain and secure additional contracts with Medicare Advantage payors on favorable terms, if at all.
• Ability to grow new physician partner relationships sufficient to recover startup costs.
• Availability of additional capital, on acceptable terms or at all, to support the business in the future.
• Significant reduction in membership.
• Transition to a Total Care Model may be challenging for physician partners.
• Inaccuracy in estimates of members' risk adjustment factors, medical services expense, incurred but not reported claims, and earnings pursuant to payor contracts.
• Public health crises, such as pandemics or epidemics, could adversely affect the company.
• The impact of restrictive clauses or exclusivity provisions in some contracts with physician partners.
• Ability to hire and retain qualified personnel.
• Ability to realize the full value of intangible assets.
• Security breaches, cybersecurity attacks, loss of data, and other disruptions to information systems.
• Ability to protect the confidentiality of know-how and other proprietary and internally developed information.
• Reliance on subsidiaries to perform and fund their operations.
• Use of algorithms, artificial intelligence, and machine learning in the business and challenges with properly managing their development and use.
• Reliance on a limited number of key payors.
• The limited terms of contracts with payors and the ability to renew them upon expiration.
• Ability to navigate the changing healthcare payor market.
• Reliance on payors, physician partners, and other providers to operate the business.
• Ability to obtain accurate and complete diagnosis data.
• Reliance on third-party software, data, infrastructure, and bandwidth.
• Consolidation and competition in the healthcare industry.
• The impact of changes to, and dependence on, federal government healthcare programs.
• Uncertain or adverse economic and macroeconomic conditions, including a downturn or decrease in government expenditures.
• Regulation of the healthcare industry and the company's and its physician partners' ability to comply with such laws and regulations.
• Federal and state investigations, audits, and enforcement actions.
• Repayment obligations arising out of payor audits.
• Negative publicity regarding the managed healthcare industry generally.
• Use, disclosure, and processing of personally identifiable information, protected health information, and de-identified data.
• Failure to obtain or maintain an insurance license, a certificate of authority, or an equivalent authorization.
• Changes in tax laws and regulations, or changes in related judgments or assumptions.
• Indebtedness and the potential to incur more debt.
• Dependence on subsidiaries for cash to fund all operations and expenses.
• Provisions in governing documents.
• Ability to achieve a return on investment depends on appreciation in the price of common stock.
• Lawsuits not covered by insurance and securities class action litigation.
• Sustainability issues.
• Stock price may be volatile.
• Non-compliance with the New York Stock Exchange could result in a delisting of securities.
• Risks related to management transitions, including the search for a permanent Chief Executive Officer, and the ability to effectively manage leadership changes.
• Ongoing implementation of performance initiatives, leadership changes, and dynamic market conditions create additional uncertainty regarding future operating and financial performance.

Future Outlook

The company anticipates a significant turnaround in 2026, targeting breakeven Adjusted EBITDA and a positive Medical Margin of $300 million to $350 million. This is expected to be driven by comprehensive business transformation initiatives, an improved rate environment, disciplined re-contracting, portfolio optimization, and a leaner operating model, despite an expected decrease in total membership and continued elevated medical cost trends. The focus for 2026 is on optimization, margin durability, and disciplined execution.

Management Comments

• "2025 was a pivotal year for agilon. We confronted challenges head-on and focused our actions to accelerate meaningful transformation across the company – enhancing execution, improving operating discipline, and fundamentally strengthening the economics of our model." Ronald A. Williams, Executive Chair.
• "While we were not satisfied by our 2025 financial performance, the transformation initiatives are delivering tangible benefits which support our expectation for material improvement in 2026." Ronald A. Williams.
• "Based on the progress we have made and the momentum we are carrying into 2026, I am confident in our trajectory and firmly believe agilon and our partners are entering the next phase with a stronger foundation, a more resilient model, and a clear path to sustainable value creation." Ronald A. Williams.

Industry Context

StockSavvy.ai notes that agilon health's focus on value-based care for senior patients, particularly within Medicare Advantage and ACO models, aligns with broader industry shifts towards outcomes-based reimbursement. The company's efforts to optimize its portfolio by exiting underperforming contracts and markets reflect a strategic response to the challenging economics and elevated medical cost trends impacting many players in the managed healthcare sector. The emphasis on improved data visibility, quality incentives, and cost discipline is critical for success in this competitive and highly regulated environment.

Comparison to Industry Standards

• NA

Management Changes

Stakeholder Impact

• Shareholders face potential stock price volatility and dependence on stock price appreciation for return on investment, as highlighted in the risks.
• Physician Partners may experience challenges transitioning to a Total Care Model, but the company aims for better alignment of incentives.
• Members may be impacted by payor contract exits and portfolio optimization, leading to a projected decrease in total membership.
• Employees are subject to cost rationalization and reductions in overhead and vendor costs as part of the operating expense reduction initiatives.

Next Steps

• Continued execution of comprehensive business transformation initiatives.
• Focus on optimization, margin durability, and disciplined execution throughout 2026.
• Ongoing search for a permanent Chief Executive Officer.
• Host a conference call to discuss fourth quarter 2025 results on February 25, 2026, at 4:30 PM Eastern Time.

Key Dates

Recommendation

While 2025 results were poor, the company has outlined a clear strategy for a significant turnaround in 2026, projecting breakeven Adjusted EBITDA and positive Medical Margin. The transformation initiatives, cost reductions, and improved contracting provide a basis for potential recovery. However, the substantial losses incurred, expected membership decline, and ongoing elevated medical cost trends warrant a cautious approach. Investors should hold to observe the execution of the 2026 strategy and confirm the projected improvements materialize.

Keywords

healthcare, Medicare Advantage, value-based care, physician partners, ACO, financial results, EBITDA, medical margin, agilon health, AGL, Q4 2025, FY 2025, 2026 guidance